B/29. Immunopharmacology I. (cytotoxic agents, retinoids). Pharmacotherapy of autoimmune diseases. Flashcards

1
Q

Drugs need to know in this topic

A

Cyclophosphamide, Methotrexate, Leflunomide, Azathioprine, Mycophenolate-mofetil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Cyclophosphamide

A

Alkylating agent (attacks guanine N7 position, dysfunctional DNA)

Ora, parenteral Requires hepatic P450 activation

  1. Hematological malignancies, breast and ovarian cancers
  2. Autoimmune diseases (SLE, GN, vasculitis)
  3. Myelosuppression 2. GI distress 3. Hemorrhagic cystitis

*Damage to the bladder is mediated by acrolein

Mesna is given as an antidote

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Methotrexate

A

Anti-metabolite (inhibitor of dihydrofolate reductase)

Oral, parenteral

Renal elimination

  1. Hematological malignancies, CNS and other solid tumors
  2. Autoimmune disease
    (RA, psoriasis)

*Toxic effects on normal cells may be reduced by
administration of folinic acid (Leucovorin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Leflunomide

A

Inhibit de-novo pyrimidine synthesis

Oral

  1. Autoimmune diseases (RA, multiple sclerosis)
  2. GI irritation
  3. Hepatotoxicity
  4. Teratogenic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Azathioprine

A

Inhibit de-novo purine synthesis

Azathioprine is rapidly converted to 6-MP

Oral, parenteral

  1. Hematological malignancies
  2. Autoimmune diseases (RA, SLE)
  3. IBD
  4. Myelosuppression
  5. Hepatotoxicity
    *Allopurinol inhibits 6-MP metabolism
    → elevated levels with increased risk for toxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Mycophenolate-mofetil

A

Inhibits de-novo GTP synthesis (inosine monophosphate dehydrogenase enzyme)
B- and T-cells are suppressed

Oral, parenteral

  1. Solid-organ transplantation
  2. Autoimmune diseases
    (SLE, GN, myasthenia, psoriasis)
  3. Myelosuppression
  4. GI distress
    *Used in combination with cyclosporine → allows dose
    reductions to limit toxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Rheumatoid arthritis

A
  • *Management of acute flare-ups**
    1. NSAID’s (no effect on disease progression)
    2. Corticosteroids (short course of oral treatment or intra-articular injection)
  • *Disease-modifying anti-rheumatic drugs (DMARD’s)**
    1. Methotrexate (1st-line agent)
    2. Chloroquine, hydroxychloroquine
    3. Leflunomide
    4. Sulfasalazine (5-ASA)
    5. Cyclosporin
    6. Tofacitinib
  • *Biological therapy**
    1. Anti-TNF-α (infliximab, adalimumab, etanercept)
    2. CTLA-4 fusion protein (abatacept)
    3. IL-1 receptor antagonist (anakinra)
    4. IL-6 receptor antagonist (tocilizumab)
    5. Anti-CD20 (rituximab)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Inflammatory bowel disease (IBD)

A
  • *Mild disease**
    1. 5-ASA
    2. Glucocorticoids – budesonide (topical, oral)
  • *Moderate disease**
    1. Glucocorticoids – prednisone (oral, IV)
    2. Azathioprine, 6-mercaptopurine
    3. Methotrexate
  • *Severe disease**
    1. Cyclosporin
    2. Anti-TNF-α (infliximab, adalimumab)
    3. Anti-IL-12 and IL-23 (ustekinumab)
    4. Anti-integrin α4β1 (natalizumab), anti-integrin α4β7 (vedolizumab)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Psoriasis

A
  • *Topical** agents
    1. PUVA therapy (psoralen and ultraviolet A)
    2. Glucocorticoids (topical)
    3. Vitamin D (topical) – inhibits keratinocyte proliferation
    4. Retinoids – Vitamin A (inhibition of cell proliferation and differentiation via binding to nuclear retinoid receptors)
  • *Systemic agents**
    1. Acitretin (inhibits synthesis of keratin precursors) – vitamin A derivative
    2. Dimethyl fumarate
    3. Apremilast (PDE-4 inhibition → decreased expression of TNF-α, IL-23, IL-17, and other inflammatory cytokines)
    4. Immunosuppressive agents – cyclosporin, methotrexate, leflunomide
  • *Biological therapy**
    1. Anti-IL-12 and IL-23 (Ustekinumab)
    2. IL-17 antagonists
    3. Anti-TNF-α (infliximab, adalimumab, etanercept)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Atopic dermatitis (eczema)

A
  • *Topical agents**
    1. Pimecrolimus (topical calcineurin inhibitor)
    2. Glucocorticoids (topical)
  • *Systemic agents**
    1. Glucocorticoids (only in severe, refractory disease)
    2. Cyclosporin
    3. Anti-IL-4 receptor α (dupilumab)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Multiple sclerosis

A
  • *Antimetabolites**
    1. Teriflunomide
    2. Cladribine (purine analogue chemotherapeutic agent)
  • *Leukocyte suppression:**
  1. Anti-CD52 (alemtuzumab)
    * *T-cell suppression**
  2. Anti-integrin α4β1 (natalizumab)
  3. Sphingosine-1-phosphate receptor modulator (fingolimod)
    * *B-cell suppression:** Anti-CD20 (ocrelizumab)
    * *Others**
  4. Interferon-β
  5. Glatiramers (mixture of short peptides corresponding to myelin building blocks)
  6. Dimethyl-fumarate (anti-oxidant effect)
  7. Fampridine (K+ channel inhibition – improves motor function)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly